The FDA has approved Tremfya (guselkumab) for the treatment of adults with moderately to severely active Crohn disease.
Recommendation based on the findings from the Phase 3 studies (GALAXI programme and GRAVITI) in Crohn’s disease 1,2,3 Beerse, Belgium (28 March 2025) – Johnson & Johnson today announced that the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback